Medicine: Tosili beads monotonica repellent treatment of ineffective and intolerable familial Mediterranean fever open label trial.

the !---- a combination of familial Mediterranean fever (FMF), but for FMF patients with autumn daffodil resistance or autumn daffodil intolerance, secondary amyloid degeneration caused by persistent inflammation is a concern.Despite reports that Toshili Bead serotonin (TCZ) is a recombinant, human-derived, anti-human leukocyte interleukin 6 receptor monoclonal antibody that prevents FMF attacks, the long-term safety and efficacy of TCZ resistance to autumn daffodils or autumn daffodil intolerance in FMF patients have not yet been evaluated.in this multicenter, open-label trial initiated by the researchers, the long-term safety of TCZ against patients who participated in placebo-controlled, randomized, double-blind, parallel group trials will assess the long-term incompatibility of ethosatoline or autumn daffodil intolerance to FMF patients.the study will be conducted at nine centres in Japan.after 24 weeks of evaluation and examination in the previous study, the trial will begin quickly.the trial will be completed when the drug is approved for FMF treatment in Japan. the main endpoint ofis the incidence of adverse events, the secondary endpoint includes the number of FMF attacks, the number of occurrences of accompanying symptoms during the attack, serum C reactive protein and amyloid amyloid A levels, the general evaluation of the doctor (100mm visual simulation scale (VAS), the general evaluation of the patient (100mm VAS) and body temperature.in general, the study is expected to provide evidence on the long-term safety of TCZ as a potential new therapeutic drug for PATIENTs with autumn daffodil resistance or autumn daffodil intolerance..